semaglutide and cancer risk GLP-1 drugs cancer: the headline is exciting. The full picture is more nuanced. New research from @ascocancer 2026 shows patients on GLP-1 medications like were up to 50% less likely semaglutide cancer cases The multifaceted

For all the experiments, rats were handled daily and habituated to intraperitoneal ( IP ) injections for one week prior to testing

32 Elafibranor (GFT505) is the first member of the PPAR-/PPAR- agonist family

Rodriguez, D

This peptide has gained significant attention in the medical and wellness communities for its potential healing properties

By combining agents known for angiogenesis, actin sequestration, and copper transport, this blend offers a unique substrate for studying multi-pathway tissue remodeling and cellular repair mechanisms in a single control environment

What side effects do patients actually experience on tesamorelin